22.05.2024 - Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted .
Although polycystic ovary syndrome is a mystery to much of medicine, emerging data about neuroendocrine involvement in the condition shed light for further research.